Among malignant lymphoproliferative disorders, an association with lymph node infarction appeared most frequently in diffuse large B-cell lymphoma (DLBCL), followed by that in follicular lymphoma (FL). However, little is known about antigen preservation in the infarcted lymphoid tissue. FLs eventually transformed to diffuse lymphomas, comprising a significant proportion of DLBCLs. To examine the antigen preservation of the follicular center cell markers in the infarcted lymphoma, we studied 7 DLBCLs and 4 FLs diagnosed concurrently with or following lymph node infarction. Sections of viable and infarcted tissue were immunostained in parallel by using a panel of antibodies effective in routinely processed, wax-embedded tissue. The panel included L26 (CD20), 56C6 (CD10), 124 (BCL-2), and polyclonal BCL-6 antibody. The present study indicated that CD20 (91%) and CD10 (80%) antigen appear to be well preserved even in infarcted lymphoma tissues and provide useful information regarding the infarcted material. However, BCL-2 (40%) and BCL-6 (0%) antigens were of little or no value in the infarcted lymphoid tissues.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/106689690401200306 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of pullulan/gellan gum films loaded with astaxanthin nanoemulsion for enhanced strawberry preservation.
Food Res Int
February 2025
College of Food Science, Guangdong Pharmaceutical University, Zhongshan, China. Electronic address:
Innovative packaging materials are essential for preserving food, serving as a substitute for petroleum-based options. In this study, biofilms consisting of pullulan and gellan gum which incorporates astaxanthin nanoemulsion were prepared to extend the shelf-life of strawberries. Hydrophobic deep eutectic solvents (DES) were used as solvents to extract natural astaxanthin from Haematococcus pluvialis.
View Article and Find Full Text PDFLipid-Rapamycin Nanovaccines Overcome the Antidrug Antibody Barrier in Biologic Therapies.
ACS Nano
January 2025
Wuya Faculty of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Antidrug antibodies (ADAs) against biologics present a major challenge for sustained biotherapy, including enzyme replacement therapies and adeno-associated virus (AAV) gene therapies. These antibodies arise from undesirable immune responses, leading to altered pharmacokinetics, reduced efficacy, and adverse reactions. In this study, we introduced a rationally designed lipid-rapamycin (Rapa)-based nanovaccine to restore immune tolerance to biologics and overcome drug resistance.
View Article and Find Full Text PDFTargeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer.
Antibodies (Basel)
January 2025
Department of Urology, Medical Center-University of Freiburg, 79106 Freiburg im Breisgau, Germany.
Background/objectives: Photoimmunotherapy (PIT) is an innovative approach for the targeted therapy of cancer. In PIT, photosensitizer dyes are conjugated to tumor-specific antibodies for targeted delivery into cancer cells. Upon irradiation with visible light, the photosensitizer dye is activated and induces cancer-specific cell death.
View Article and Find Full Text PDFBeneficial effects on T cells by photodynamic therapy with talaporfin enhance cancer immunotherapy.
Int Immunol
January 2025
Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Photodynamic therapy (PDT), a local cancer treatment using photosensitizers, has been reported to enhance antitumor immune responses by inducing immunogenic cell death. Although several studies have demonstrated the synergistic antitumor effects of PDT and immune checkpoint blockage (ICB), the detailed underlying mechanisms remain poorly understood. In this study, we investigated the immunological effects of PDT with talaporfin (Tal-PDT), a clinically approved photosensitizer, using bilateral tumor-bearing mouse models.
View Article and Find Full Text PDFTriple knockdown of , , and in T cells reduces CAR-T cell toxicity but preserves activity against solid tumors in mice.
Sci Transl Med
January 2025
Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Chimeric antigen receptor (CAR)-T cell therapies have revolutionized the landscape of cancer treatment, in particular in the context of hematologic malignancies. However, for solid tumors that lack tumor-specific antigens, CAR-T cells can infiltrate and attack nonmalignant tissues expressing the CAR target antigen, leading to on-target, off-tumor toxicity. Severe on-target, off-tumor toxicities have been observed in clinical trials of CAR-T therapy for solid tumors, highlighting the need to address this issue.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!